Detalhe da pesquisa
1.
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
Trials
; 22(1): 765, 2021 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34732236